S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10

PharmAust Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume3.27 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive PAA News and Ratings via Email

Sign-up to receive the latest news and ratings for PharmAust and its competitors with MarketBeat's FREE daily newsletter.

About PharmAust

PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for human and animal healthcare. The company develops drug discovery intellectual property for the treatment of various cancers in humans and animals. Its lead candidate is Monepantel, which are in Phase II clinical trials for the treatment of cancer. The company also provides highly specialized medicinal and synthetic chemistry services on a contract basis to clients to the drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.


No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales
$3.66 million
Book Value
A$0.03 per share





Next Earnings Date


Overall MarketRank

1.32 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

PharmAust (ASX:PAA) Frequently Asked Questions

What stocks does MarketBeat like better than PharmAust?

Wall Street analysts have given PharmAust a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PharmAust wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are PharmAust's key executives?

PharmAust's management team includes the following people:
  • Dr. Roger Aston B.Sc., BSc (Hons), Ph.D., Exec. Chairman & Acting CEO (Age 65, Pay $284.7k)
  • Mr. Sam Michael Wright A.C.I.S., M.A.I.C.D., AFin, DipAcc, ACIS, MAICD, Fin. Director, Company Sec. & Director (Age 43, Pay $132.2k)
  • Dr. Richard Mollard, Chief Scientific Officer
  • Mr. Robert Charles Bishop, Exec. Director
  • Mr. Colin La Galia, Chief Exec. Officer of Epichem Pty Ltd
  • Ms. Rebecca McCrackan, Director of Epichem Pty Ltd

What is PharmAust's stock symbol?

PharmAust trades on the ASX under the ticker symbol "PAA."

How much money does PharmAust make?

PharmAust has a market capitalization of $0.00 and generates $3.66 million in revenue each year.

How many employees does PharmAust have?

PharmAust employs 2,020 workers across the globe.

What is PharmAust's official website?

The official website for PharmAust is www.pharmaust.com.

Where are PharmAust's headquarters?

PharmAust is headquartered at 333 Clay St Ste 1600, Houston, Texas 77002-4101.

How can I contact PharmAust?

PharmAust's mailing address is 333 Clay St Ste 1600, Houston, Texas 77002-4101. The company can be reached via phone at 61 8 6161 7412.

This page was last updated on 10/25/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.